Sponsored Videos

Robert Bloder, Chief Business Officer, Ascendia Pharmaceuticals, highlights traits that a (bio)pharmaceutical company look for when identifying a CDMO to support drug development and manufacturing programs.

Ascendia Pharmaceuticals CEO, Jim Huang, describes how new opportunities in formulation development complement the company’s previous work in developing novel nanotechnologies to support biopharmaceutical development.

Societal™ CDMO's J. David Enloe and Erica Raether discuss the fundamentals of maintaining a strong company culture during times of change.

Wesley Tatum, PhD (Principal Engineer, Process & Product Development, Serán Bioscience) shares insights surrounding formulation and process development that focus on the future of the industry.

Leverage artificial intelligence (AI) for a more streamlined GMP manufacturing process.

LIGHTHOUSE Instruments introduces new technology for robust headspace data generation and areas of application.

Dr Seán McMahon explains how Ashland’s Viatel™ bioresorbable work and rationalizes why formulators should consider using in the development of long acting injectables and implants.

Enrico Barichello, Product Manager for the Syringe Platform at Stevanato Group, discusses the risks associated with the interaction between primary packaging and complex novel therapeutics and describes how to prevent or manage concerns utilizing newer, pre-sterilized syringe systems that have more unique characteristics.